Browsing Tag
rademikibart
2 posts
Connect Biopharma cuts asthma treatment failures 66%, but endpoint misses significance
Connect Biopharma’s rademikibart reduced 28-day treatment failures by approximately 66% in a 160-patient Phase 2 acute-asthma study, but the primary endpoint missed statistical significance even as lung-function improvement reached significance and management prepares to discuss a Phase 3 programme with the FDA.
What rademikibart Phase 3 data could mean for Connect Biopharma’s immunology strategy (NASDAQ: CNTB)
Connect Biopharma’s rademikibart Phase 3 eczema data will debut at AAD 2026. Discover what it means for biologic competition and Connect Biopharma strategy.